Strategic Funding Presidio Medical has secured recent Series C funding totaling 72M and ongoing investor interest, signaling strong financial backing and potential for scaled clinical trials, regulatory milestones, and expanded manufacturing partnerships.

Board Expansion Addition of new board members including Richard J. Buchholz and David Neustaedter indicates active governance and strategic guidance, creating opportunities to engage with investors and advisors for collaboration, partnerships, and potential strategic alliances.

Neuromodulation Focus The company is clinical-stage with a transformational neuromodulation platform targeting diseases of undesired neural activity and an initial indication in chronic pain, suggesting sales opportunities with hospitals, pain clinics, and neuromodulation device distributors seeking innovative solutions.

Growth Persona With a lean team of 11-50 employees and ongoing leadership hires, there is likely a need for critical vendors, contract manufacturers, clinical trial services, and regional sales or field support to accelerate development and commercialization.

Market Positioning Funding history from Invus Opportunities and coverage by MarketWatch and Lexology point to visibility in the medtech space; align outreach with strategic accounts in chronic pain and neuromodulation, leveraging potential partnerships with regulated manufacturers and payer discussions.